Menu
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Hims & Hers Health Stock a Buy?


Hims & Hers Health (NYSE: HIMS) stock has been on a bit of a rollercoaster ride this year. The stock is down about 35% from the highs it hit earlier this year, but is it still up over 85% year to date. As such, investors should probably expect some volatility when investing in the stock.

Let's look at three things investors should consider when contemplating an investment in Hims & Hers and whether the stock is ultimately a buy, sell, or hold at current levels.

Hims & Hers has quietly been one of the strongest growth companies in the healthcare space in the last few years. In 2022, the telemedicine operator grew its revenue by 94%, followed by 65% growth in 2023. That growth continued into 2024, with first-quarter revenue growth of 46% and second-quarter growth of 52%, representing total revenue growth of 49% in the first half.

Continue reading


Source Fool.com

Like: 0
Share

Comments